Merck/Schering-Plough Pharmaceuticals
Press Releases
Information About the SEAS Study
Information About the ENHANCE Trial
Frequently Asked Questions
Home
About Us
Patient Assistance Program
Responsibility and Compliance
Company News
Press Releases
Information About the SEAS Study
Information About the ENHANCE Trial
Frequently Asked Questions
MERCK/Schering-Plough Pharmaceuticals

Frequently Asked Questions

What is the purpose of the Merck/Schering-Plough Pharmaceuticals joint venture?

Merck & Co., Inc., and Schering-Plough Corporation formed this joint venture to develop and market new prescription medicines for cholesterol management.

Where is Merck/Schering-Plough Pharmaceuticals headquartered?

Our headquarters are located at:
351 N. Sumneytown Pike
PO Box 1000
North Wales, PA 19454

What products does Merck/Schering-Plough offer?

Currently, Merck/Schering-Plough offers 2 medicines: VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe). To learn more about these products, visit vytorin.com and zetia.com.

How do I know if the medicines developed by Merck/Schering-Plough are right for me?

Talk to your doctor to determine whether VYTORIN or ZETIA are right for you.

Who can answer my questions about Merck/Schering-Plough Pharmaceuticals?

For questions regarding press and media, contact Skip Irvine at 267-305-5397. For questions regarding VYTORIN, call 1-877-VYTORIN; for questions regarding ZETIA, call 1-800-98-ZETIA. For all other questions, call 1-866-637-2501.

Where can I find corporate information about Merck/Schering-Plough Pharmaceuticals?

Corporate information about Merck & Co., Inc., and Schering-Plough Corporation, including annual reports for these companies, is available online at merck.com and schering-plough.com.